Related Experiment Videos
Reduced IL-2 level concentration in patients with breast cancer as a possible risk factor for relapse
S Arduino1, M Tessarolo, R Bellino
1Chair B, Gynecology and Obstetrics Institute, University of Torino, Italy.
Abstract:
Reduced interleukin 2 (IL-2) production has been described as one of the most frequent immune dysfunctions observed at relapse in patients with disseminated solid neoplasms. It was seen that patients treated for breast cancer (NED-no evidence of disease- at check-up) have a relapse percentage of 4.7% if the IL-2 plasmatic level is normal while the relapse percentage increased to 33.3% if it is low after a 10-12 month follow-up. This link between low IL-2 and the host immune response is a new prognostic indicator and one not strictly related to the tumour itself.
Insights
Low interleukin 2 (IL-2) levels are linked to higher relapse rates in cancer patients. Monitoring IL-2 offers a new immune-based prognostic indicator for cancer recurrence.
Area of Science:
- Immunology
- Oncology
Background:
- Reduced interleukin 2 (IL-2) production is a common immune dysfunction in patients with advanced solid tumors.
- Immune system status is critical in cancer progression and relapse.
Purpose of the Study:
- To investigate the prognostic value of plasma interleukin 2 (IL-2) levels in patients with disseminated solid neoplasms, specifically breast cancer.
- To establish IL-2 as a potential indicator of host immune response and cancer relapse risk.
Main Methods:
- Observational study analyzing plasma IL-2 levels in breast cancer patients post-treatment.
- Follow-up assessment of disease status (no evidence of disease vs. relapse) over a 10-12 month period.
- Correlation analysis between IL-2 levels and relapse rates.
Main Results:
- Patients with low IL-2 levels exhibited a significantly higher relapse rate (33.3%) compared to those with normal IL-2 levels (4.7%) after 10-12 months.
- A clear association was found between reduced IL-2 production and increased risk of cancer recurrence in breast cancer patients.
Conclusions:
- Low plasma IL-2 is a novel and significant prognostic indicator for cancer relapse in patients with disseminated solid neoplasms.
- IL-2 levels reflect host immune response, offering a prognostic marker independent of tumor-specific factors.